Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

November 2007, Regeneron Pharmaceuticals ($REGN @Regneron) entered into a global, strategic collaboration with Sanofi ($SNY @Sanofi) to discover, develop, and commercialize fully human monoclonal antibodies (the “Antibody Collaboration”). The Antibody Collaboration is governed by the companies’ Discovery and Preclinical Development Agreement (“Antibody Discovery Agreement”) and a License and Collaboration Agreement. Upfront Payment $85MM for Regeneron […]

Applied Genetic Technologies (Gainesville, FL), a clinical-stage biotechnology company focused on respiratory and retinal diseases, closed a $37.5M Series B financing. Participants include Alta Partners, S.R. One, Osage University Partners, InterWest Partners, Intersouth Partners and MedImmune Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds […]

Imagen Biotech (United Kingdom) a commercial-stage biotechnology assay company focused on analysis of signal transduction pathways and target validation, closed a $40M Series A financing. Participants include SV Life Sciences, Novo Ventures and Fidelity Biosciences.

Innopharma (Piscataway, NJ) a development-stage specialty pharmaceutical company focused on generics and drug delivery technology platforms for existing drugs, closed a $15M Series A financing. Participants include Thomas, McNerney & Partners.

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners. Thanx for your patience as we catch-up.

Averdo (Waltham, MA) a commercial-stage ophthalmology medical device company focused on procedures for biomechanically strengthening and modifying the cornea, closed on $25M Series C financing. Participants include SCP Vitalife, Aperture Venture Partners, Prism VentureWorks, De Novo Ventures, Flagship Ventures, Borealis Ventures and Echelon Ventures. Thanx for your patience as we catch-up.

Amakem (Belgium) a development-stage pharmaceutical company focused on glaucoma and other ophthalmic indications, closed a $25.3M Series A financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.

Altacor (United Kingdom) a commercial-stage ophthalmic specialty pharmaceutical company focused on ocular surface disease and glaucoma, closed a $3M Series C bringing the total financing to $5.4M. Participants include NVM Private Equity, Enterprise Ventures, Beringea and Esperante Ventures.

PanOptica (Mount Arlington, NJ) a development-stage biopharma company focused on in licensing IND-stage ophthalmology assets, closed a $30M Series A financing. Participants include SV Life Sciences and Third Rock Ventures.

Aerie Pharmaceuticals (Bridgewater, NJ) a clinical-stage biotechnology company focused on the treatment of glaucoma and other ophthalmic disease, closed a $41.3M Series B financing. Participants include Alta Partners and Sofinnova Ventures.

Inotek Pharmaceuticals (Lexington, MA) a clinical-stage small molecule company focused on age-related macular degeneration, glaucoma, cataract and diabetic retinopathy, closed a $18M Series D financing. Participants include Devon Park Bioventures, Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures and Bio One Capital.

EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.

Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

« Previous Entries  Next Page »

to top of page...